REVIEW ARTICLE

Use of Lymphatic Systems for Absorption of Nano-particles

Yousef A. M. Qarmout, S. Hari Hara Sudhan, Mohamed Omer Mahmoud Idris

Department of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education and Research College, Anantapur, Andhra Pradesh, India

Abstract

The process of drug delivery through the lymphatic system is difficult and complex and also follows a physiological uniqueness system. There is an important role that the lymphatic pathways show in the transport of fluids outside the cell, and they can be avoided the first-pass metabolism of the lymphatic system is distinguished by its ability to assess disease states and progressive diseases-based lipids Nano-formulation in the lymphatic system. Solid lipid nanoparticles, for example, have extraordinary features that make them attractive candidates for lymphatic delivery. For colloidal carrier systems, these formulations are excellent because it has controlled release characteristics and provide greater stability of chemicals to drug molecules. Lipid-based Nano-formulations for absorption and distribution are wanted to be subject to interstitial obstruction during drug delivery regulation; there are factors such as the size of the particle, weight of the molecules, and charge of the surface depends on the absorption and distribution by the lymphatic system of the lipid-based nano-formulation, lipid forms important factors also affect the drugs delivery through the lymphatic system.

Key words: Absorption, lymphatic system, nano-particles, nano-structured lipid carriers, solid lipid nano-particles

INTRODUCTION

The lymphatic pathway of the circulatory system is a portion of a complicated conduit network that holds a clear fluid, clear fluid known as lymph. The lymphatic system's roles are to restore the water balance in the body by restoring fluid that has leaked back to the systemic circulation in the interstitial space and supplying the immune cells to the nodes of the lymph.[1,2] There is a specialized function of the lymphatic system in unique areas. The lymphatic system performing an important part in long-chain fatty-acid absorption, cholesterol-esters, tri-glycerides, and lipid-soluble vitamins.[2,3] There are many benefits of drug distribution through the lymphatic system, overcoming first-pass liver metabolism, and targeting therapies for illness that propagate through the lymphatic system.[4] An active function is demonstrated by the lymphatic pathway in the body-wide movement of infectious agents and cancer cells. There are several ways to distribute medications into the lymphatic channels of the intestines.[4,5] First of all, single-layered, non-fenestrated endothelial cells are composed of lymphatic capillaries. In the lymphatic vasculature, the cells are organized in a strongly overlapping manner to form a porous wall, allowing macromolecular targeting of the lymphatic system.[3] Hence, with the aid of an absorption enhancer, enhanced absorption of hydrophilic macromolecules, and macro conjugates will open up the paracellular pathway.[6,7] Secondly, lymphoid tissue connected with the gut consists of either isolated or clumped lymph follicles shaping the patches of Peyer, and the lymphatic supply with an entry point for medication.[4] Finally, through transcellular absorption, P-glycoprotein paracellular transport and cytochrome P450 inhibition, the main route through the intestinal walls is lipid transport. The development of chylomicrons is associated with the transfer into the lymphatic system of lipophilic compounds.[6] Numerous lipid-based details, along with emulsions, micellar frameworks, liposome's, self-emulsifying drug dispatching frameworks, self-emulsifying drug transport frameworks, self-emulsifying drug delivering frameworks, solid lipid

Address for correspondence:
Mr. Yousef A. M. Qarmout, Department of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education and Research College, Anantapur, Andhra Pradesh, India.
E-mail: yousef.a.qarmout@gmail.com

Received: 14-10-2021
Revised: 14-12-2021
Accepted: 24-12-2021

nano-particles (SLNs), and nano-structure lipid carriers (NLCs), have been recognized as medication transporters for the lymphatic framework.[8] The lymphatic system anatomy decides the distribution of the therapeutic agent, that is, the lymphatic vessel's endothelial wall architecture offers a substantial open area to simplify the distribution of polymers with a complex of high molecular weight drugs. In actuality, the lymphatic framework was designed to assume a negative part in the engendering of illness in the body; another section on the job of the lymphatic framework in the metastasis of disease was opened by late investigations.[9] The study of particular lymph endothelium markers and transcription factors, such as vascular endothelial growth factor, presented the potential for specific drug targeting to decrease lymph angiogenesis and metastasis of the lymph system. Methods of lymphatic imaging play a crucial role in the evolution of drug distribution to target systemic lymphatic disease, such as human malignancy, preparing therapy.[9,10] In the first step of development during metastasis, the disease pervades the lymphatic system. To assess both the state of the disorder and the efficacy of drug treatment, lymphatic imaging methods may be used. Visible dye and radionuclide imaging methods do not reveal simple pictures; new methods have been shown to have better sensitivity and maximum accuracy, such as magnetic resonance imaging, fluorescence imaging, nano-carriers, and quantum dots thus minimizing unnecessary biopsies or healthy nodal tissue removal.[5]

NANO-PARTICLES DEPENDENT ON LIPIDS BASED

Lipid-based nanoparticles are often separated into two categories, that is, SLNs and NLCs, including a solid matrix. As an alternative to colloid medication carriers, including liposomes, nano-capsules, nano-emulsions, and micro-emulsions, SLNs were identified in the early 1990s.[4] Compared to other networks of colloidal carriers, both SLNs and NLCs have many benefits. This transporter framework can also be built on a large scale, including controlled medication release and improving the synthetic dependability of medication molecules.[5,11]

SLN

SLNs show an eminent benefit other than nano-particulate systems since they use biological lipids and surfactants, both of which are known as protective.[3] The broadly utilized lipids in the arrangement of SLNs are monoglycerides, diglycerides and fatty oils, waxes, and unsaturated fats. Surfactants, for example, polysorbate and poloxamer are getting all the more much of the time utilized,[10,11] Moreover, avoiding a solvent will help avoid the issue of carrier biotoxicity in humans through using high-pressure homogenization, SLNs consist of the development of a relatively hardcore composed of solid lipids at room temperature. SLNs can also assist in improving stabilization, and provide controlled release and targeting of drugs. The small size of this formulation allows drugs to be effectively absorbed into the intestine, especially through the lymphatic route, involving particles with a diameter of only 20–500 nm.[5] For the transport of cytotoxic agents, absorption through the lymphatic route may be used to defeat the drawbacks of non-specificity, drug resistance, and serious toxicity. In SLNs, including idarubicin, methotrexate, and etoposide, cytotoxic drugs have been incorporated. Notwithstanding, conventional intravenous division of cytotoxic medications has limited tumor assimilation because of negligible admittance to the tumor, abbreviated flow time because of quicker freedom by the phagocytic framework, and diminished focusing on. Thus, alternative routes of administration, along with subcutaneous, pulmonary, and duodenal routes, have been explored for SLN's.[1,4]

SUBCUTANEOUS LYMPHATIC DELIVERY ROUTE FOR SLNS

Harivardhan *et al*. performed various routes of implementation for etoposide-loaded glycerol tripalmitate (ETPL) in SLNs in mice carrying Dalton's cancer. Bio-distribution comparison of radiolabeled unrestricted etoposide and radiolabeled ETPL nanoparticles across three completely various routes, that is, blood vessels, body, and intraperitoneal coverage.[12] Etoposide and ETPL nanoparticles have been named 99mTc (Technetium) exploitation and have been observed using a gamma radiation spectroscope and gamma scintigraphy. Body covering administration demonstrated superior neoplasm uptake at 24 h compared with each administration of intraperitoneal and blood vessels, with 8 times stronger drug uptake than intraperitoneal and 59-fold stronger drug influx than blood vessel pathways. Conjoint administration of body covering showed a substantial decrease in drug absorption by system organs (i.e., lung, liver, and spleen) that resulted in the longer circulation of ETPL nanoparticles. Conjointly, this route had a comparatively low tissue distribution, which could scale back the effects of etoposide in the general aspect. Initial uptake by the ETPL nanoparticles neoplasm once body-protecting implementation was weak, but over time improved. This slow deposition of ETPL nanoparticles suggests that it is necessary to handle medical care. A prescription shot neighboring the neoplasm site may likewise be a more secure course for chemotherapeutic specialists of lymph-related injuries than vein or intraperitoneal organization.[12]

PULMONARY PATH FOR LYMPHATIC DELIVERY SLNS

In related types of cancer, targeted delivery of SLN through the pneumonic pathway has a critical ability.[10] Some solid endocrine tumors exhibit high levels of pathological process

proliferation, such as tiny cell respiratory organ cancer. These tumors grow at the beginning through one hemithorax and its local humor nodes; they ultimately travel to the blood circulation through the vascular system. This kind of cancer metastasis relies on the evacuation of the humor nodes.[10,13] Furthermore, alveolar leeway of medication particles up to a specific breadth is required by the vascular framework (200 nm). This makes SLN drug targeting possible, and a variety of other studies are carried out involving the delivery of SLNs through nebulization and sequence medical assistance in patients with carcinoma. The SLN methodology, which is generally utilized in the administration of non-cell cellular breakdown in the lungs, has been created utilizing paclitaxel. The nebulization of paclitaxel-stacked SLNs in this investigation was contrasted with the organization of paclitaxel alone by veins utilizing a standard detailing for the assurance of respiratory organ metastases in MXT-B2 cell vaccinated mice.[13] A significant 20-fold drop in the oppressive concentration of fifty cellular growth values (IC50) and a 19.43 percentage reduction in viable cells compared to the delivery of paclitaxel alone to the blood vessels are incontestable treatments with paclitaxel-loaded SLNs. The approach of the SLNs demonstrated an absence of poisonousness related to delayed, disliked paclitaxel of the vein, recommending that SLN conveyance have high properties and low course.[11]

INTESTINAL PATH FOR LYMPHATIC DELIVERY SLNS

The most well-liked drug delivery path is the gastrointestinal tract (GIT). However, because of its distinctive anatomy and physiology, many variables could have an effect on drug bioavailability, including the solubility of the drug within the GIT, the pH within the tract, and even the number of hours spent there.[3] This route jointly subjects medicine to the liver's presystemic metabolism, which reduces the drug's absorption rate. The lymphatic absorption of SLNs is also abused by introducing drugs into SLNs to circumvent first-pass metabolism to beat this.[9] Several research teams have studied this and found increased bioavailability once intraduodenally administered SLNs that incorporate medication. In methotrexate-loaded SLNs, the superior absorption of the antimetabolite through the vascular system and into the bloodstream was incontestable. During this analysis, victimization saturated fatty acid, monostearin, tristearin, and Compritol® 888 ATO were investigated for the effects of different forms of lipid-based SLN's. Intra-small intestine administration of methotrexate-loaded SLN's exhibited a better absorption rate of methotrexate despite the types of lipids used, with the best increase ascertained in comparison to methotrexate in SLN's containing Compritol 888 ATO. A 10-overlay ascends in methotrexate levels was seen inside the lymphatic framework with methotrexate-stacked SLN's comparative with the methotrexate arrangement. In contrast to an idarubicin solution for intra small intestine and intravenous administration, another study integrated idarubicin into SLN's associate. Small intestine system organization of idarubicin-stacked SLN's improved the medication's bioavailability. This joint examination showed that the appropriation of idarubicin to the guts, lungs, spleen, and kidneys was lower, which could limit the cardio-toxicity of idarubicin. As a result of the 30-fold improvement in the removal half-life of idarubicin-loaded SLN's compared to idarubicin solution, SLN's were urged to be helpful as a prolonged release system. Once idarubicin-stacked SLN's were controlled intraduodenally contrasted with intravenous steady definition organization, the following space under the bend was mutually appeared in the examination. These outcomes show that medications created by SLN's can give exact focused on drug conveyance to build restorative adequacy and lessening the poisonousness of oral antitumor specialists.[7]

NLC

To beat the lipid-based NLC mechanism was created by the shortcomings of SLNs, such as drug loading into a solid matrix and drug expulsion during storage due to polymorphic alteration of the lipid particles. Only one lipid style is used by SLNs, that is, a hefty lipid that arranges the medication between the chains of carboxylic corrosive glyceride. In contrast, NLC's use in a mixture to create a controlled nanostructure of each solid and liquid lipid. Imperfections within the lipids provide spaces to handle the medication inside the structure, contributing to most drug loading capabilities. In addition, NLCs throughout preparation and storage are less susceptible to gelation than SLNs. In this manner, NLCs are considered to address a second era of lipid nanoparticle details.[11]

NANO-STRUCTURED LIPID CARRIERS' SUBCUTANEOUS ROUTE FOR LYMPHATIC DELIVERY

An ideal lymphatic course of appropriation for lipid nanoparticles is the subcutaneous strategy, with a few advantages such as medication maintenance at the spot of organization for a delayed timeframe, low-leeway, supported delivery, and improvement of ingestion. During subcutaneous tissue organization, lipid nanoparticles will not, in general, be moved directly into the bloodstream as a result of capillary management of water porosity and small molecules. Instead, the lymphatic capillaries near the subcutaneous injection site absorb lipid-based nanoparticles.[11] The absorption into the lymphatic system of those lipid-based nanoparticles totally depends on the nanoparticles' dimensions. At the injection site, larger lipid nanoparticles accumulate, subsequently, the substance is released gradually from the nano-particles. The free medication can enter the blood dissemination through

pores on the dividers of the vessels. More modest lipid nanoparticles (under 0.1 μm) are just gotten to and packed in territorial lymph hubs by the lymphatic vessels. Thus, supported by these benefits, due to the need for enhanced chemical chemistry properties relative to alternative lipid-based Nano-carrier structures, NLC's can be produced through subcutaneous administration as a carrier for the delivery of lymphatic drugs.[11,14]

PULMONARY PATH FOR LYMPHATIC DELIVERY OF NANO-STRUCTURED LIPID CARRIERS

The oral and parenteral paths are contrasted with drug administration via the pulmonic path, which has many advantages. The pulmonary pathway prevents the first-pass metabolism, decreases general toxicity, is non-invasive, reduces the need for constant dosing, enables the distributed medications directly from the respiratory system to obtain hard-to-reach components, and enables the initial drug concentration to be amplified.[10] There is a good potential for NLC's to be delivered through the lymph circulation by the pulmonary pathway. Due to their diffusion value, the size of NLC particles is decreased to only 500 nm, which, due to their size, could increase drug deposition within the tissue of the respiratory organ. NLCs are lipid nanoparticles that can be used as a vector to target small cell carcinomas and viral drugs that cause human immune disorders, both of which can enter the circulatory system via the lymphatic system.[10] NLCs are lipid nanoparticles that can be used as a vector to target small cell carcinomas and viral drugs that can enter the circulatory system through the lymphatic system. Have the potential to supply a drug delivery mechanism and will have an inflated efficacy compared to SLN's.[7]

INTESTINAL PATH FOR LYMPHATIC DELIVERY OF NANO-STRUCTURED LIPID CARRIERS

As a consequence of the increased solubility and enhanced bioavailability of hydrophobic or poorly soluble oral medicinal products in water, NLC's have the potential to be a good technique for oral drug delivery. There are numerous ancient colloidal drug carriers among the standard lipid-based formulations.[8] They created drug-stacked NLCs to increase the oral bioavailability of vinpocetine. Male Wistar rats were administered orally with all vinpocetine-loaded NLCs and a vinpocetine suspension.[9] The time expected to accomplish the most noteworthy plasma fixations (T_{max}) and subsequently the greatest focus achieved (C_{max}) for hanging vinpocetine was extraordinary for 30 min and (354.29 ± 57.49 ng/ml), while the T_{max} and C_{max} of vinpocetine-stacked NLCs were extreme for a time of an hour and a half and (679.29 ± 133.57 ng/ml), individually. For vinpocetine-loaded NLCs, the T_{max} was 1 h longer than for vinpocetine suspension, referring to the transport of NLCs into circulation indirectly. In addition, C_{max} was substantially greater than vinpocetine suspension for vinpocetine-loaded NLC's. For vinpocetine-loaded NLC's, the domain under the curve was 3.2 times larger than that of the vinpocetine suspension. According to a pharmacokinetic *in vivo* study, the relative bioavailability of vinpocetine-loaded NLCs increased by 322%. These findings recommend the oral bioavailability of medicinal products which are poorly soluble in water in the area be increased by NLC's. One explanation for the increased bioavailability of vinpocetine may be that inside the lymphatic system, the area unit of NLC's is transported, therefore avoiding the first-pass metabolism, for the most part, which is the primary source of poor bioavailability.[9]

MODEL USED IN THE STUDY OF THE MOVEMENT OF DRUGS IN THE LYMPHATIC SYSTEM

In the *in-vivo* model, animals are cannulated in the mesenteric or thoracic lymphatic ducts to study drug delivery within the intestinal lymphatic system. The medication amounts in the liquid body's substance can be specifically calculated using this formula. The procedure should not be carried out on humans since it is a permanent and invasive surgical procedure.[9] Tiny animals, including rats, are typically used, although this model has also been used for certain larger animals, as well as sheep, pigs, rabbits, and dogs. The lymphatic venous shunt in the *in vivo* model, where the amounts of drugs in the lymph are measured over a fixed period of time, and the lymph is extracted over a longer period time. In addition, the related indirect technique was used in the associated oral bioavailability analysis to assess the transport of intestinal lymphatic drugs in the presence of intestinal chylomicron flow inhibitors and the absence of intestinal chylomicron flow inhibitors. Like the lymphatic duct injection model, this procedure has the benefit of not needing surgical care.[15]

MODELS OF *IN VITRO*

Various *in vitro* models may be used instead of *in vivo* models. The territory unit of Caco-2 cells cannot assess intracellular lipoprotein-lipid gathering and inspect the effect of lipids and lipid excipients on the consolidation of lipoprotein drugs into the lymphatic vehicle in the model of intestinal penetrability. Medication retention can be anticipated *in vivo* by ascertaining drug discharge from a lipid-based medication conveyance system and foreseeing drug precipitation during lipolysis.[15]

THE FACTORS INFLUENCING THE TRANSFER OF NANOPARTICLES THROUGH THE LYMPHATIC SYSTEM

In lipid-based nano-carriers, anticancer, anti-HIV, and immunosuppressive molecules have been integrated into GI molecules. In the gastrointestinal epithelium, researchers studied the ingestion and delivery of lipid-based nano-carriers to the peripheral lymphatic duct.[8] There are groups that have stated that the lymphatic system collects lipid-based nanoparticles and distributes them in the lymphatic circulation according to the path of administration. In order to influence the absorption and division of lipid-based nanoparticles within the lymphatic circulation, other variables such as surface charge, size, and molecular charge have been observed. Weight, hydrophobicity, some lipid types, and emulsifier concentration have also been observed.[16]

NANO-PARTICLES SIZE

The size and design of Nano-particles assume a significant part in lymphatic assimilation and molecule conservation in lymph hubs. Transporters, for example, colloidal and lipid particles improve in lymphatic retention. Medication particles, for example, anticancer and monoclonal antibodies are incorporated into dendrimers and lipid-containing nanoparticles such as liposomes, SLNs, and NLCs dependent on their size and the accessibility of arrangements for lymphatic focusing. According to Oussoren and Storm.,[5] a particle size of 10–100 nm administered subcutaneously is suitable for lymphatic uptake. Particles smaller than 10 nm are absorbed by the systemic circulation, while particles larger than 100 nm are absorbed preferentially by the lymphatic system. Particles larger than 100 nm, on the other hand, were not specifically defined. Moreover, the agents found that an interstitial infusion of particles more prominent than 100 nm was slowly devoured and that the particles remained bound for quite a while at the infusion site.[5]

SURFACE CHARGE OF NANOPARTICLES

The surface charge on a drug carrier is important. Owing to the presence of negative charge in the interstitial matrix, it is rumored that negatively charged carriers such as dendrimers, proteins, polylactic-co-glycolic acid nano-spheres, and lipid-based nanoparticles (e.g., liposomes) indicate greater lymphatic absorption than neutral or positive charge surfaces. Changes in negatively charged particles have been reported in lymph nodes for a longer period of time. Charged particles inside the interstitium, on the other hand, face considerable resistance to manoeuvring through the charged interstitium matrix due to the multiplied electro-static attraction force. Details relating to the ionic nature of carrier particles provide the alphabetic character potential. For a power- <-30 mV, zeta potentials indicate anionic activity, while strengths between +10 and -10 mV indicate neutral behavior, and values >+30 mV indicate cationic behavior. Kaur *et al*. tested zidovudine-loaded liposomes with either positive (stylamine) or negative (diacetyl phosphate) surfactants. To target the lymphatic system.[3,11]

DRUG MOLECULAR WEIGHT

A subcutaneous pathway shows a linear association between molecular weight and macromolecule absorption range in the delivery of lymphatic drugs. Growing molecular weight allows the capillaries to minimise the absorption of molecules and multiply the uptake at the injection site. The lymphatic system is a system that transfers waste from the body to the lymph node. Molecules weighing <1000 Da are consumed without difficulty into the lymphatic circulation by the capillaries before they are taken in, by contrast, compounds weighing >16,000 Da are absorbed by the lymphatic system rather than the capillaries.[3,5]

NANO-PARTICLES HYDROPHOBICITY

Hydrophobicity is critical in simplifying the lymphatic absorption of lipid-based Nano formulations from the administration location. Depending on their surface properties, the hydrophobicity of the particles is primarily responsible for phagocytosis and lymphatic uptake. It suggests that reducing the hydrophobicity of bacteria will minimise phagocytosis. Opsonization may be increased because opsonin is very readily linked to hydrophobic surfaces as opposed to hydrophilic surfaces. Phagocytosis could increase lymphatic absorption due to this phenomenon.[3]

DRUGS PARTITION COEFFICIENT AND LIPID SOLUBILITY

The physical and chemical properties of a drug, as well as its lipid solubility and drug splitting coefficient, are crucial in lymphoid drug transport. The variance in lymph transport may be due to the discrepancy between the drugs in the solubility of triglycerides.[7]

LIPID TYPES THAT ARE USED IN NANO-PARTICLES

Lipid-based nano-formulations are comprised of fatty oils that are organized so that the polar head is presented to the fluid stage. In Lipid-Based Nano-formulations, the composition of lipids can influence their absorption through polar intestinal epithelial cells during the transcellular path. The design of this particle is indistinguishable from that of

chylomicrons.[14] These other methotrexate-loaded SLN preparations use solvent in a diffusion technique with four different lipid forms, that is, ATO, Monostearin, Stearic Acid, and Tristearin from Compritol 888. The details were analyzed as far as size, charge, morphology, drug protection, *in vitro* discharge, and pharmacokinetic properties. The methotrexate-stacked SLN's, as Compritol 888 ATO, had the most noteworthy snare execution and the smallest scale when contrasted with the other three lipid types. The all-encompassing chain length of glyceryl behenate, which upgrades the interchain addition position of the methotrexate atom, can explain Compritol 888 ATO's benefit over different lipids. The examiners found that methotrexate-Compritol 888 ATO SLN's would be advised to bioavailability more than other methotrexate-stacked SLN plans. Using mesenteric duct cannulation within an anesthetized albino rat model, researchers measured lymphatic absorption at the study site. The lymphatic medication fixation uncovered that the methotrexate-Compritol 888 ATO SLN's plan would do better for lymphatic ingestion than the other methotrexate-stacked SLN definitions. Besides, the analysts found a connection between their *in vitro* and site discoveries.[14,17]

CONCLUSION

Present approaches to lymphatic distribution of lipid-based nano-formulations have been checked. With higher first-pass metabolism and reduced solubility for cytotoxic agents and therapeutic molecules, the lymphatic system opens up new distribution possibilities. This technique works well as a bypass route, particularly for anti-cancer and anti-HIV drugs, which both target diseases through the lymphatic system. NLCs, which are medications encapsulated in advanced lipid-based Nano formulations, are better candidates for lymphatic drug distribution. As lymphatic drug delivery mechanisms, lipid-based Nano formulations should be very exciting with sufficient enhancement and selection of an efficient administration path.

REFERENCES

1. Yáñez JA, Wang SW, Knemeyer IW, Wirth MA, Alton KB. Intestinal lymphatic transport for drug delivery. Adv Drug Deliv Rev 2011;63:923-42.
2. Iqbal J, Hussain MM. Intestinal lipid absorption. Am J Physiol Endocrinol Metab 2009;296:E1183-94.
3. Paliwal R, Rai S, Vaidya B, Khatri K, Goyal AK, Mishra N, Mehta A, *et al.*, Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomed Nanotechnol Biol Med 2009;5:184-91.
4. Hawley AE, Davis SS, Illum L. Targeting of colloids to lymph nodes: Influence of lymphatic physiology and colloidal characteristics. Adv Drug Deliv Rev 1995;17:129-48.
5. Oussoren C, Storm G. Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev 2001;50:143-56.
6. Ling SS, Magosso E, Khan NA, Kah HY, Barker SA. Enhanced oral unavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug Dev Ind Pharm 2006;32:335-45.
7. Jenning V, Thünemann AF, Gohla SH. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 2000;199:167-77.
8. Liu J, Wong HL, Moselhy J, Bowen B, Wu XY, Johnston MR. Targeting colloidal particulates to thoracic lymph nodes. Lung Cancer 2006;51:377-86.
9. Zhuang CY, Li N, Wang M, Zhang XN, Pan WS, Peng JJ, *et al.* Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm 2010;394:179-85.
10. Videira MA, Botelho MF, Santos AC, Gouveia LF, De Lima JJ, Almeida AJ. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drug Target 2002;10:607-13.
11. Porter CJ, Charman WN. Uptake of drugs into the intestinal lymphatics after oral administration. Adv Drug Deliv Rev 1997;25:71-89.
12. Reddy LH, Sharma RK, Chuttani K, Mishra AK, Murthy RS. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J Control Release 2005;105:185-98.
13. McAllaster JD, Cohen MS. Role of the lymphatics in cancer metastasis and chemotherapy applications. Adv Drug Deliv Rev 2011;63:867-75.
14. Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: A mechanistic update. Adv Drug Deliv Rev 2008;60:702-16.
15. Abadi I, Imron C, Bachrowi MM, Fitriyanah DN. Design and implementation of battery charging system on solar tracker based stand-alone PV using fuzzy modified particle swarm optimization. AIMS Energy 2020;8:142-55.
16. Cai S, Yang Q, Bagby TR, Forrest ML. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev 2011;63:901-8.
17. Trotta M, Debernardi F, Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int J Pharm 2003;257:153-60.

Source of Support: Nil. **Conflicts of Interest:** None declared.